한빛사
>
한빛사논문
한빛사논문
- 조회1,537
Gastroenterology, Published online: July 15, 2018 | DOI: https://doi.org/10.1053/j.gastro.2018.07.008
Changing Trends in Etiology-based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.
Donghee Kim, MD, PhD1,*, Andrew A. Li, MD2, Chiranjeevi Gadiparthi, MD3, Muhammad Ali Khan, MD3, George Cholankeril, MD1, Jeffrey S. Glenn, MD, PhD1, Aijaz Ahmed, MD1
1Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, United States
2Department of Medicine, Stanford University School of Medicine, Stanford, CA, United States
3Division of Gastroenterology and Hepatology, University of Tennessee Health Science Center, Memphis, TN, United States
*Corresponding Author: Donghee Kim, M.D., Ph.D.
Division of Gastroenterology and Hepatology Stanford University School of Medicine 300 Pasteur Drive, Stanford, CA 94304
Abstract
Background & Aims
Although treatment of hepatitis C virus (HCV) infection has improved, the prevalence of alcoholic liver disease (ALD) has been increasing, so we need an updated estimate of the burden and etiology-specific mortality of chronic liver diseases. We studied the trends in age-standardized mortality of chronic liver diseases among adults 20 years or older in the United States (US), from 2007 through 2016.
Methods
We collected data from the US Census and National Center for Health Statistics mortality records, identifying individuals with HCV infection, ALD, nonalcoholic fatty liver disease (NAFLD), or hepatitis B virus (HBV) infection using ICD-10 codes. We obtained temporal mortality rate patterns using joinpoint trend analysis with estimates of annual percentage change (APC).
Results
Age-standardized HCV-related mortality increased from 7.17/100,000 persons in 2007 to 8.14/100,000 persons in 2013, followed by a marked decrease in the time period at which patients began receiving treatment with direct-acting antiviral agents (from 8.09/100,000 persons in 2014 to 7.15/100,000 persons in 2016). The APC in HCV mortality increased 2.0%/year from 2007 through 2014, but decreased 6.4%/year from 2014 through 2016. In contrast, age-standardized mortality increased for ALD (APC of 2.3% from 2007 through 2013 and APC of 5.5% from 2013 through 2016) and NAFLD (APC of 6.1% from 2007 through 2013 and APC of 11.3% from 2013 through 2016). HBV-related mortality decreased steadily from 2007 through 2016, with an average APC of -2.1% (95% CI, -3.0 to -1.2). Etiology-based mortality in minority populations were higher. HCV-related mortality (per 100,000 persons) was highest among non-Hispanic blacks (10.28) and whites (6.92), followed by Hispanics (5.94), and lowest among non-Hispanic Asians (2.33). Non-Hispanic Asians had higher mortality for HBV infection (2.82 per 100,000 vs 1.02 for non-Hispanic blacks, and 0.47 for non-Hispanic whites).
Conclusion
In our population-based analysis of chronic liver disease mortality in the US, the decline in HCV-related mortality coincided with the introduction of direct-acting antiviral therapies, while the mortality from ALD and NAFLD increased during the same period. Minorities in the US have disproportionately higher chronic liver disease-related mortality.
논문정보
- Research article
- 2018년 07월 (BRIC 등록일 2018-08-24)
- 국외 연구진
- 의약학 > 응용의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
